New Stock News | Chengdu Olymvax Biopharmaceuticals Inc (688319.SH) plans to list on the Hong Kong Stock Exchange. The China Securities Regulatory Commission requires clarification on whether the business involves the development and application of genetic diagnostic technology listed in the negative list.

On March 2nd, the China Securities Regulatory Commission announced the disclosure of supplementary materials required for overseas issuance and listing filing (February 9, 2026 - March 2, 2026). The Commission requested Chengdu Olymvax Biopharmaceuticals Inc to provide clarification on whether its and its subsidiaries' actual business activities involve the development and application of human stem cells, gene diagnosis, and treatment technologies as specified in the "Special Management Measures for Foreign Investment Access (Negative List)" (2024 version), and to provide clear basis for this. According to the disclosure by the Hong Kong Stock Exchange on November 25, 2025, Chengdu Olymvax Biopharmaceuticals Inc (688319.SH) submitted an application to list on the main board of the Hong Kong Stock Exchange, with CITIC SEC as the exclusive sponsor. The prospectus shows that Chengdu Olymvax Biopharmaceuticals Inc is a global, innovation-driven biopharmaceutical company dedicated to the research, development, production, and commercialization of innovative vaccines. The company's strategic focus is on the two major areas of unmet medical needs, "super bacterial vaccines" and "adult vaccines". The company has commercialized three products: tetanus adsorbed vaccine, Haemophilus influenzae type b conjugate vaccine (or Hib conjugate vaccine), and Meningococcal group A and C polysaccharide conjugate vaccine (or AC conjugate vaccine). According to the Zhoushi Consultancy Report, Chengdu Olymvax Biopharmaceuticals Inc's tetanus adsorbed vaccine has maintained a leading market position in China during the reporting period, with a market share exceeding 80% from 2022 to 2024.